Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ICMT | O60725 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238953 | 0.86 | USP30 (0.37) | CYP11B2CYP11B1KDM1A | |
| SCHEMBL4234192 | 0.81 | HRH3 (0.44) | — | |
| SCHEMBL4240943 | 0.78 | CA12 (0.49) | PDE4B | |
| SCHEMBL21501064 | 0.70 | AR (0.60) | ARCYP11B2CYP11B1PDE4BKDM1A | |
| SCHEMBL4237914 | 0.70 | KDM1A (0.36) | CYP11B2CYP11B1KDM1A | |
| SCHEMBL29490258 | 0.68 | AR (0.66) | ARCYP11B2CYP11B1PDE4BKDM1A | |
| SCHEMBL509522 | 0.68 | AR (0.66) | ARCYP11B2CYP11B1PDE4BKDM1A | |
| SCHEMBL4234289 | 0.67 | MEN1 (0.32) | — | |
| SCHEMBL523610 | 0.66 | HRH3 (0.61) | ARCYP11B2ALKPDE3BPDE3A | |
| SCHEMBL6941777 | 0.65 | AR (0.49) | ARCYP11B2CYP11B1PDE4BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | AR 1029/4885CYP11B2 535/4885CYP11B1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.